CytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript)

CytomX Therapeutics, Inc. (NASDAQ:CTMX) CX-2051 Phase 1 Interim Clinical Data in Advanced Colorectal Cancer May 12, 2025 8:00 AM ET

Company Participants

Sean McCarthy – Chairman and CEO
Chris Ogden – CFO
Wayne Chu – Chief Medical Officer

Conference Call Participants

Roger Song – Jefferies
Anupam Rama – JPMorgan
Peter Lawson – Barclays
Robert Driscoll – Wedbush Securities
Daniel Smith – H.C. Wainwright

Operator

Good morning, everyone, and thank you for standing by. Welcome to the CytomX Therapeutics CX-2051 Phase 1 Interim Clinical Data Call. Please be advised that today’s call is being recorded. I would now like to hand the call over to your host for today, Chris Ogden, CytomX’s Chief Financial Officer. Please go ahead.

Chris Ogden

Thank you. Good morning and thank you for joining us. Before we begin, I would like to remind everyone that during this call, we will be making forward-looking statements. Because forward-looking statements relate to the future, they’re subject to inherent uncertainties and risks that are difficult to predict and many of which are outside of our control. Important risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future developments, or otherwise.

Earlier today, we issued a press release that includes a summary of our first quarter 2025 financial results and highlights recent progress at CytomX. Additionally, this morning we are excited to announce both positive interim Phase 1 data for CX-2051 in advanced colorectal cancer, as well as a $100 million financing with a leading group of healthcare investors. The focus of our call today will the Phase 1 data for CX-2051. For details on the company’s financial results and pipeline updates, we encourage everyone to read today’s press releases and the associated materials, which have